Skip to main content

Menu

Martindale: The Complete Drug Reference June 2022 Update

This update contains 9 new monographs and 1 existing monograph has been updated. Preparations have been updated for 3 countries.

New monographs:

  • Abrocitinib is a Janus kinase inhibitor that is used in the treatment of atopic eczema.
  • Levoketoconazole is the 2S,4R-enantiomer of ketoconazole, a potent inhibitor of cortisol synthesis. It is used in the treatment of endogenous Cushing’s syndrome when surgery is not an option or has not been curative.
  • Maribavir is an orally active benzimidazole riboside antiviral drug used for the treatment of post-transplant CMV infection refractory to standard antiviral drugs.
  • Molnupiravir is an oral prodrug with antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is used in the treatment of mild to moderate COVID-19 (coronavirus disease 2019) infection.
  • Nirmatrelvir is an inhibitor of coronavirus 3C-like protease that is used in the treatment of COVID-19 infection in patients who do not require oxygen supplementation and are at increased risk of progressing to severe infection.
  • Ponesimod is an immunomodulator used in the treatment of relapsing forms of multiple sclerosis, including relapsing-remitting disease and active secondary progressive disease, and in clinically isolated syndrome.
  • Tezepelumab is a recombinant human monoclonal antibody that binds to and inhibits thymic stromal lymphopoietin. It is used in the management of severe asthma.
  • Tucatinib is an orally active tyrosine kinase inhibitor of the human epidermal growth factor receptor 2 (HER2). It is used with trastuzumab and capecitabine in the treatment of HER2-positive locally advanced or metastatic breast cancer.
  • Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that is used in the acute treatment of migraine.

Notable revisions:

  • Tofacitinib: major adverse cardiovascular events, including myocardial infarction, stroke, and cardiovascular death, have been reported in patients taking Janus kinase (JAK) inhibitors.

Updated names, synonyms and codes; official standards; official preparations:

  • Ph Eur 10.1, 10.2, and 10.3
  • USP-NF 2021 Issue 2

Proprietary Preparations and Manufacturers updated for the following countries and regions:

  • Italy
  • UK†
  • USA†

† Countries updated on an ongoing basis